ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering at-risk patients and caregivers to protect against severe allergic reactions that may lead to anaphylaxis [3] - The company is commercializing neffy® 2 mg (trade name EURneffy® in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [3] Upcoming Events - ARS Pharmaceuticals will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco [1] - Richard Lowenthal, Co-Founder, President and CEO, will present on January 15, 2025, at 7:30 a.m. PT, and management will engage in one-on-one meetings with investors [2] - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days [2]